PMID- 37803911
OWN - NLM
STAT- MEDLINE
DCOM- 20240104
LR  - 20240116
IS  - 1442-2042 (Electronic)
IS  - 0919-8172 (Linking)
VI  - 31
IP  - 1
DP  - 2024 Jan
TI  - Prostate-specific antigen follow-up and management for patients undergoing 
      holmium laser enucleation of the prostate.
PG  - 82-87
LID - 10.1111/iju.15315 [doi]
AB  - OBJECTIVES: To investigate who needs a careful postoperative monitoring for 
      prostate cancer (PCa) after holmium laser enucleation of the prostate (HoLEP). We 
      examined characteristics and oncological outcomes of HoLEP-related PCa. METHODS: 
      Patients who underwent HoLEP during 2002-2017 in a Japanese tertiary center were 
      retrospectively analyzed. Patients were divided into non-PCa, PCa with HoLEP 
      specimen (PCa-Ope), and PCa diagnosed during follow-up (PCa-Post). Outcomes of 
      all HoLEP-related PCa were monitored. RESULTS: Of the total 758, 60 (7.9%) were 
      diagnosed with PCa from resected specimen of HoLEP and 9 (1.2%) were diagnosed 
      postoperatively. Preoperative prostate-specific antigen (iPSA), postoperative PSA 
      (pPSA), and PSA density were significantly higher in both PCa groups than those 
      in non-PCa group. While iPSA significantly correlated to prostate volume (PV), 
      pPSA was not associated with PV. A receiver-operating-characteristics curve 
      demonstrated that pPSA 1.2 ng/mL achieved the optimal cut-off (AUC 0.95) for the 
      incidence of PCa-Post. In addition to the incidence of PCa and iPSA, lower 
      enucleation efficiency (enucleated volume /PV) was significantly associated with 
      pPSA >1.2 ng/mL. Among PCa-Ope, 51 were Grade Group (GG) </=2 and 42 were 
      followed-up with active surveillance, whereas 8 of 9 PCa-Post were GG >/=3 and 2 
      progressed to death. CONCLUSIONS: Patients undergoing HoLEP are associated with 
      some risk of potential PCa. While oncological outcomes were favorable among 
      PCa-Ope, postoperative PSA should be carefully monitored even if not diagnosed 
      with PCa with HoLEP specimen. Enucleation efficiency should be also considered 
      not to misread pPSA value.
CI  - (c) 2023 The Japanese Urological Association.
FAU - Kimura, Shingo
AU  - Kimura S
AUID- ORCID: 0000-0003-2164-3091
AD  - Department of Urology, Sendai City Hospital, Sendai, Japan.
AD  - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Katayama, Hiromichi
AU  - Katayama H
AUID- ORCID: 0000-0001-8339-5164
AD  - Department of Urology, Sendai City Hospital, Sendai, Japan.
AD  - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Ohara, Eiichiro
AU  - Ohara E
AUID- ORCID: 0000-0003-2419-1772
AD  - Department of Urology, Sendai City Hospital, Sendai, Japan.
FAU - Aoki, Hiroshi
AU  - Aoki H
AD  - Department of Urology, Sendai City Hospital, Sendai, Japan.
FAU - Shibuya, Rie
AU  - Shibuya R
AD  - Department of Pathology, Sendai City Hospital, Sendai, Japan.
FAU - Naganuma, Hiroshi
AU  - Naganuma H
AD  - Department of Pathology, Sendai City Hospital, Sendai, Japan.
FAU - Ishidoya, Shigeto
AU  - Ishidoya S
AUID- ORCID: 0000-0002-1652-0735
AD  - Department of Urology, Sendai City Hospital, Sendai, Japan.
FAU - Ito, Akihiro
AU  - Ito A
AD  - Department of Urology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20231006
PL  - Australia
TA  - Int J Urol
JT  - International journal of urology : official journal of the Japanese Urological 
      Association
JID - 9440237
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Male
MH  - Humans
MH  - Prostate-Specific Antigen
MH  - Prostate/surgery
MH  - *Prostatic Hyperplasia/surgery/complications
MH  - Follow-Up Studies
MH  - Retrospective Studies
MH  - *Lasers, Solid-State/therapeutic use
MH  - *Laser Therapy/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - HoLEP
OT  - biopsy
OT  - prostate cancer
OT  - prostate-specific antigen
EDAT- 2023/10/07 11:42
MHDA- 2024/01/04 11:44
CRDT- 2023/10/07 02:02
PHST- 2023/04/04 00:00 [received]
PHST- 2023/09/20 00:00 [accepted]
PHST- 2024/01/04 11:44 [medline]
PHST- 2023/10/07 11:42 [pubmed]
PHST- 2023/10/07 02:02 [entrez]
AID - 10.1111/iju.15315 [doi]
PST - ppublish
SO  - Int J Urol. 2024 Jan;31(1):82-87. doi: 10.1111/iju.15315. Epub 2023 Oct 6.